课题基金 / 基金详情

项目摘要

项目成果

OSNAT HERZBERG的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):贾第鞭毛虫是一种折磨贫困国家的人类病原体,也是美国腹泻爆发的最常见原因。贾第鞭毛虫已被疾病控制与预防中心列为B类生物恐怖主义生物。在美国,最受欢迎的抗贾第虫病药物是甲硝唑或替硝唑,这些化合物有不良的副作用。此外,对药物的耐药性增加和复发也是一个问题。因此,很明显,需要替代药物治疗。我们开发了一种基于滋养体ATP含量的贾鞭毛虫生物发光活力测定方法,适用于高通量筛选,并将该方法小型化,适用于1536孔板的化合物筛选。我们建议筛选NIH化合物文库,并首先使用CHO细胞和后来的CACO-2细胞研究命中化合物的选择性。具有低IC50的选择性化合物的最小致死浓度将通过再生长实验确定。对于一些最热门的目标,贾第鞭毛虫靶点的鉴定将进行,如果成功,将推进到基于结构的化合物优化。
英文摘要
DESCRIPTION (provided by applicant): Giardia lamblia is a human pathogen afflicting impoverished nations, and the most common cause of outbreaks of diarrhea in the United States. Giardia has been classified by the CDC as a category B bioterrorism organism. The favored anti giardiasis drugs in the US are metronidazole or tinidazole, compounds that have undesirable side effects. Moreover, increasing resistance to drug regimes and recurrence are a concern. It is thus clear that alternative drug treatments are needed. We have developed a bioluminescence Giarida viability assay based on the trophozoites ATP content that is suitable for high throughput screening and miniaturized the assay for compound screening in 1536-well plates. We propose to screen the NIH compound library and investigate the selectivity of hit compounds using initially CHO cells and later CACO-2 cells. The minimum lethal concentration of selective compounds exhibiting low IC50 will be determined by re- growth experiments. For a few top hits, identification of the Giardia target will be undertaken and if successful, advanced to structure-based compound optimization. PUBLIC HEALTH RELEVANCE: Giardia lamblia is a human pathogen afflicting billions of people annually and a category B bioterrorism organism. Giardiasis treatments have undesirable side effects, recurrence, and increasing drug resistance. To facilitate discovery of better drugs, we have developed a Giardia viability assay and miniaturized it for high throughput compound screening. This assay will be used to screen the NIH compound library and identify compounds that kill Giardia trophozoites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs
  • 批准号:
    9089862
  • 项目类别:
  • 资助金额:
    $20.9万
  • 财政年份:
    2015
  • 负责人:
    OSNAT HERZBERG
  • 依托单位:
Fumagillin Derivatives as Novel Antigiardiasis and Antiamebiasis Drugs
  • 批准号:
    8960227
  • 项目类别:
  • 资助金额:
    $20.9万
  • 财政年份:
    2015
  • 负责人:
    OSNAT HERZBERG
  • 依托单位:
Identification and in vitro experimental investigation of missense SNPs implicate
  • 批准号:
    8366038
  • 项目类别:
  • 资助金额:
    $28.88万
  • 财政年份:
    2012
  • 负责人:
    OSNAT HERZBERG
  • 依托单位:
Identification and in vitro experimental investigation of missense SNPs implicate
  • 批准号:
    8534208
  • 项目类别:
  • 资助金额:
    $27.87万
  • 财政年份:
    2012
  • 负责人:
    OSNAT HERZBERG
  • 依托单位:
海外基金